Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against uniQure N.V. on behalf of stockholders who suffered losses between September 24 and October 31, 2025. The lawsuit claims that uniQure made materially false statements regarding the approval of its pivotal study design by the FDA, and downplayed risks related to potential delays in its Biologics License Application (BLA) timeline. Investors can apply to be lead plaintiffs until April 13, 2026, and are encouraged to reach out for more information on their legal rights.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against uniQure, alleging false and misleading statements.
  • The company's pivotal study design was not fully approved by the FDA, raising significant regulatory concerns.
  • There has been a disclosure that uniQure may need to delay its BLA timeline due to additional studies.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
If you purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, both dates inclusive (the “Class Period”). Investors have until April 13, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
If you purchased or otherwise acquired uniQure shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the class action lawsuit against uniQure about?

The lawsuit claims uniQure made misleading statements regarding its business operations.

Who can participate in the class action lawsuit?

Individuals who purchased uniQure shares between September 24, 2025, and October 31, 2025.

How can I contact Bragar Eagel & Squire regarding the lawsuit?

You can call them at (212) 355-4648 or email investigations@bespc.com.

What is the deadline to apply as lead plaintiff in the lawsuit?

Investors must apply by April 13, 2026, to be considered as lead plaintiff.

Where is Bragar Eagel & Squire located?

The firm has offices in New York, South Carolina, and California.

Last updated: Mar 19, 2026